Zichao Zhao1, Qilun Liu2, Chunmei Wu3, Wenjing Guo4, Jinping Li2. 1. Chifeng Cancer Hospital, Chifeng 024000, China. 2. General hospital of ningxia Medical University, Yinchuan 750004, China. 3. Ningxia Medical University, Yinchuan 750004, China. 4. Dezhou Second People's Hospital, Dezhou 253000, China.
Abstract
OBJECTIVE: To study the expression of G9a in human breast cancer, its association with the clinicopathological characteristics of breast cancer, and its effect on the proliferation of breast cancer cells. METHODS: A total of 122 specimens of breast cancer tissues and 61 adjacent normal tissues resected between October, 2016 and October, 2017 were obtained from the Tissue Bank of Ningxia Medical University General Hospital. Immunohistochemistry and real-time PCR were used to detect the expression of G9a in the breast cancer tissues. The relationship of G9a with the clinicopathological features of the patients, molecular subtypes of breast cancer and the immunohistochemical markers was analyzed. A bioinformatics approach was used to analyze the expression of G9a in breast tissues and its association with the prognosis of the patients with breast cancer. UNC0631, a G9a inhibitor, was used to investigate the effect of G9a on the proliferation of breast cancer cells in vitro. RESULTS: The results of immunohistochemical study, real-time PCR and bioinformatics analysis showed that G9a was highly expressed in human breast cancer tissues. G9a was highly expressed in breast invasive ductal carcinoma, and its expression was negatively correlated with age (P < 0.05). Her-2-overexpressing breast cancer showed high expressions of G9a, which was positively correlated with the expressions of Her-2, Ki-67 and E-cadherin (P < 0.05). Bioinformatics analysis suggested that a high G9a expression was an independent risk factor for poor prognosis of breast cancer. In cultured breast cancer cells, the application of the G9a inhibitor significantly inhibited the cell proliferation. CONCLUSIONS: G9a is highly expressed in breast cancer tissues to promote the development and progression of breast cancer. A high G9a expression is an independent risk factor for poor prognosis of breast cancer, and G9a may serve as a new target for early diagnosis and treatment of breast cancer.
OBJECTIVE: To study the expression of G9a in humanbreast cancer, its association with the clinicopathological characteristics of breast cancer, and its effect on the proliferation of breast cancer cells. METHODS: A total of 122 specimens of breast cancer tissues and 61 adjacent normal tissues resected between October, 2016 and October, 2017 were obtained from the Tissue Bank of Ningxia Medical University General Hospital. Immunohistochemistry and real-time PCR were used to detect the expression of G9a in the breast cancer tissues. The relationship of G9a with the clinicopathological features of the patients, molecular subtypes of breast cancer and the immunohistochemical markers was analyzed. A bioinformatics approach was used to analyze the expression of G9a in breast tissues and its association with the prognosis of the patients with breast cancer. UNC0631, a G9a inhibitor, was used to investigate the effect of G9a on the proliferation of breast cancer cells in vitro. RESULTS: The results of immunohistochemical study, real-time PCR and bioinformatics analysis showed that G9a was highly expressed in humanbreast cancer tissues. G9a was highly expressed in breast invasive ductal carcinoma, and its expression was negatively correlated with age (P < 0.05). Her-2-overexpressing breast cancer showed high expressions of G9a, which was positively correlated with the expressions of Her-2, Ki-67 and E-cadherin (P < 0.05). Bioinformatics analysis suggested that a high G9a expression was an independent risk factor for poor prognosis of breast cancer. In cultured breast cancer cells, the application of the G9a inhibitor significantly inhibited the cell proliferation. CONCLUSIONS:G9a is highly expressed in breast cancer tissues to promote the development and progression of breast cancer. A high G9a expression is an independent risk factor for poor prognosis of breast cancer, and G9a may serve as a new target for early diagnosis and treatment of breast cancer.
Entities:
Keywords:
G9a; breast cancer; expression; proliferation
Authors: Chenfang Dong; Yadi Wu; Jun Yao; Yifan Wang; Yinhua Yu; Piotr G Rychahou; B Mark Evers; Binhua P Zhou Journal: J Clin Invest Date: 2012-03-12 Impact factor: 14.808
Authors: Jing Huang; Jean Dorsey; Sergei Chuikov; Laura Pérez-Burgos; Xinyue Zhang; Thomas Jenuwein; Danny Reinberg; Shelley L Berger Journal: J Biol Chem Date: 2010-01-29 Impact factor: 5.157
Authors: André Hennigs; Fabian Riedel; Adam Gondos; Peter Sinn; Peter Schirmacher; Frederik Marmé; Dirk Jäger; Hans-Ulrich Kauczor; Anne Stieber; Katja Lindel; Jürgen Debus; Michael Golatta; Florian Schütz; Christof Sohn; Jörg Heil; Andreas Schneeweiss Journal: BMC Cancer Date: 2016-09-15 Impact factor: 4.430
Authors: E C Inwald; M Klinkhammer-Schalke; F Hofstädter; F Zeman; M Koller; M Gerstenhauer; O Ortmann Journal: Breast Cancer Res Treat Date: 2013-05-16 Impact factor: 4.872